Connect with us



US biotech secures $47 million funding

|13 September 2016|


Proclara Biosciences has secured $47 million in funding to support its work in fighting Alzheimer’s, Parkinson’s and other debilitating diseases.

The American biotechnology company – formerly NeuroPhage Pharmaceuticals – is a leader in the development of novel therapies for diseases like these – caused by protein misfolding.

“We are very pleased by the continued support of our investors, which speaks to the strength of our science and the tremendous potential for our therapies to transform the treatment landscape for patients suffering from Alzheimer’s and other neurodegenerative diseases,” said Franz Hefti, Ph.D., president and chief executive officer of Proclara. “Together with our name change, this important corporate milestone marks our continued progress towards bringing to market a new class of medicines to address the urgent needs of patients suffering from debilitating protein misfolding diseases.”

Newsletter Signup

Written By

Iain is an experienced writer, journalist and lecturer, who held editorships with a number of business focussed publications before co-founding and becoming editor of Innovators Magazine. Iain is also the strategic director for OnePoint5Media.


greener greener

Biotech paves way to greener future


race race

Impact of race on biotechnology


Biotech transforming our world


Biotech & …


Newsletter Signup